Cargando…

p38 MAPK Inhibition Mitigates Hypoxia-Induced AR Signaling in Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: Progression of prostate cancer to a castration-resistant state is associated with poor patient outcomes, and new therapeutic targeting approaches are needed. Poorly oxygenated (hypoxic) cancer cells are resistant to many treatment modalities, and it is therefore important that novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Serina, Jain, Pallavi, So, Jonathan, Shahidi, Saeid, Chung, Stephen, Koritzinsky, Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922949/ https://www.ncbi.nlm.nih.gov/pubmed/33671134 http://dx.doi.org/10.3390/cancers13040831

Ejemplares similares

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

Emerging proteins involved in castration-resistant prostate cancer via the AR-dependent and AR-independent pathways (Review)
por: Feng, Kangle, et al.
Publicado: (2023)

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()
por: Qiao, Yuanyuan, et al.
Publicado: (2016)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth
por: Luo, Jun, et al.
Publicado: (2020)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
por: Shah, Supriya, et al.
Publicado: (2016)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2017)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Longitudinal dynamics of the tumor hypoxia response: From enzyme activity to biological phenotype
por: Lee, Sandy Che-Eun S., et al.
Publicado: (2023)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
por: Gu, Peng, et al.
Publicado: (2019)

RF27 | LBSUN342 Ar-targeted Linked-read Sequencing Reveals Complex Ar Structural Variants In Castration Resistant Prostate Cancer Models
por: Zivanovic, Andrej, et al.
Publicado: (2022)

Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
por: Qu, Yuanyuan, et al.
Publicado: (2015)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
por: Luo, Jun
Publicado: (2016)

A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer
por: Capaia, Matteo, et al.
Publicado: (2018)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
por: Simon, Iris, et al.
Publicado: (2021)

KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer
por: Lu, Dingheng, et al.
Publicado: (2021)

The threshold energy for the reaction $^{38}$Ar(p,n)$^{38}^{m}$K
por: Burcham, William Ernest, et al.
Publicado: (1978)

Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models
por: Thomas, Elizabeth, et al.
Publicado: (2022)

Hypoxia regulates CD9-mediated keratinocyte migration via the P38/MAPK pathway
por: Jiang, Xupin, et al.
Publicado: (2014)

ADAM17 Mediates Hypoxia-Induced Keratinocyte Migration via the p38/MAPK Pathway
por: Zhu, Guoqin, et al.
Publicado: (2021)

Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy
por: Liao, Yuning, et al.
Publicado: (2020)

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020)

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
por: Kim, Seaho, et al.
Publicado: (2022)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Hypoxia‐inducible factor 1A inhibition overcomes castration resistance of prostate tumors
por: Terzic, Julie, et al.
Publicado: (2023)

Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer
por: Cameron, Sarina, et al.
Publicado: (2023)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

Transcriptomic Profiling Analysis of Castration-Resistant Prostate Cancer Cell Lines Treated with Chronic Intermittent Hypoxia
por: Lee, Chung Lyul, et al.
Publicado: (2022)

NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis
por: Jeter, Collene R, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b3hfvjf4fqsarmlm6evdl9gd70